MOHS SURGERY FOR NMSC IS IT REALLY NESESSARY???

Similar documents
If Mohs surgery is the 'gold standard for non-melanoma skin cancer treatment', why doesn't everyone have it? Antonio Ji Xu University of Oxford

Clinical Policy Title: Indications for Mohs micrographic surgery

The Role of Mohs Micrographic Surgery in Skin Cancer Treatment

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Evidence for Mohs surgery

MOHS MICROGRAPHIC SURGERY

Clinical Policy Title: Indications for Mohs micrographic surgery (MMS)

Skin Cancer as a Contraindication to Organ Transplantation

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Iatrogenic Immunosuppression and Cutaneous Malignancy

For additional information on meeting the criteria for Mohs, see Appendix 2.

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Interesting Case Series. Aggressive Tumor of the Midface

CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge

ALASKA ARIZONA IDAHO MONTANA NORTH DAKOTA OREGON SOUTH DAKOTA UTAH WASHINGTON WYOMING

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas

I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Mohs. Micrographic Surgery. For Treating Skin Cancer

Better health with the best cosmetic result, no one can ask more from a surgical

Corporate Medical Policy

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial

BRITISH ASSOCIATION OF DERMATOLOGISTS WORKING PARTY REPORT ON SETTING STANDARDS FOR MOHS MICROGRAPHIC SURGERY SERVICES

FDA INDICATIONS Mohs surgery is a procedure and is not regulated by the Food and Drug Administration.

Incomplete excision of basal cell carcinoma (BCC) in the head and neck region: to wait, or not to wait?

Outcomes in Oncology

University College Hospital. Mohs micrographic surgery. Dermatology Services

Skin Cancer of the Nose: Common and Uncommon

New and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ

MOHS SURGERY -The Myth and the Truth-

SKIN CANCER AFTER HSCT

Frequently Asked Questions

Department of Dermatology, Queen Margaret & Victoria Hospitals

Policy #: 127 Latest Review Date: June 2011

MING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1)

Nonmelanoma skin cancers

Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018

STUDY. Mohs Micrographic Surgery and Surgical Excision for Nonmelanoma Skin Cancer Treatment in the Medicare Population

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Mohs surgery for the nail unit

Skin Cancer 101: Diagnosis and Management of the Most Common Cancer

Summary. Electronic brachytherapy for the treatment of nonmelanoma skin cancer is considered investigational.

Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery

ONCOLOGY DERMATOLOGY AND SURGERY Dr. Pedro Redondo

Munich Method of Micrographic Surgery for Basal Cell Carcinomas: 5-year Recurrence Rates with Life-table Analysis

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Periocular skin cancer

Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary

Analysis of effectiveness of a surgical treatment algorithm for basal cell carcinoma *

Disclosures. I have no conflicts of interest to disclose

Skin NCG (Anglia East & Anglia West)

JAM ACAD DERMATOL VOLUME 76, NUMBER 2. Research Letters 351

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY

Clinical Study Basal Cell Carcinoma: 10 Years of Experience

Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma

PanMidlands Ocular Cancer Pathway March 2008 Approved by The Midland Oculoplastic Surgery Society

Clinical Study Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma

STUDY. Nonmelanoma Skin Cancer Mortality ( ) Conclusions: Misclassifying the cause of death as nongenital. (NMSC) is the most

STUDY. Predictors of Extensive Subclinical Spread in Nonmelanoma Skin Cancer Treated With Mohs Micrographic Surgery

Incidence and Trends of Cutaneous Malignancies in the Netherlands,

Living Beyond Cancer Skin Cancer Detection and Prevention

British Society for Dermatological Surgery Undergraduate Essay Prize "There is no need to treat any skin cancer with Mohs surgery - discuss"

Mohs Micrographic Surgery

The Reverse Galeal Hinge Flap: Another Valuable Technique in the Repair of Scalp

Single Technology Appraisal (STA) Vismodegib for treating basal cell carcinoma [ID1043]

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Summary. Electronic brachytherapy for the treatment of nonmelanoma skin cancer is considered investigational.

Modalities of Radiation

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Mohs Micrographic Surgery A Patient Guide

HDR Brachytherapy for Skin Cancers. Joseph Lee, M.D., Ph.D. Radiation Oncology Associates Fairfax Hospital

Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response

Syddansk Universitet. The Danish Nonmelanoma Skin Cancer Dermatology Database

Alcohol should be avoided for 3 days prior to surgery and 2 days after the procedure.

Pearls for Keeping it Simple in Cutaneous Reconstruction

General information about skin cancer

Clinical Practice Guide. Basal cell carcinoma, squamous cell carcinoma (and related lesions) a guide to clinical management in Australia

SKIN SERVICES REVIEW Changes to Medicare Benefits Schedule for 1 November 2016

Cutaneous Adnexal Tumors

Basal cell carcinoma 5/28/2011

5/20/2015. Mohs Surgery BCCA High risk anatomic locations. Mohs Surgery High risk anatomic locations. Mohs Surgery Histologically Aggressive BCCA

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

2009 Accepted Abstracts

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Disclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose

Mohs. Micrographic Surgery

A Multi Site Prospective Study of the Adverse Events and Complications Associated with Mohs Micrographic Surgery. Nicole Y. Lee

Eyelid basal cell carcinoma Patient information

Mohs surgery. Information for patients Dermatology

Oliver J. Wisco, DO, FAAD Melanoma Specialist & Mohs Surgeon Bend Memorial Clinic

Technicians & Nurses Program

Mohs Micrographic Surgery

Periocular Malignancies

NASAL SEPTUM ADENOID CYSTIC CARCINOMA: A CASE REPORT

Dermatology Foundation

Transcription:

MOHS SURGERY FOR NMSC IS IT REALLY NESESSARY??? Mariana Zamir, MD MOHS and Dermatosurgery Unit Department of Dermatology Hadassah - Hebrew University Medical Center Jerusalem

Why talking about Mohs surgery???

NMSC incidence is confnuously rasing The total number of registered NMSCs in the US popula>on in 2006 was 3,507,693 and the total number of persons in the United States treated for NMSC about 2,152,500. The expected incidence is thought to be about 4,000,000 new NMSC cases every year. Rogers HW1, Weinstock MA, Arch Dermatol. 2010 Mar;146(3):283-7.

Skin cancer treatment costs are rapidly increasing From 1996 to 2008, the total number of skin cancer treatment procedures [excision, destruc>on, and Mohs micrographic surgery (MMS)] increased by 53% increase The uflizafon of MMS increased drama>cally by 400% between the years 1995-2009, one out of four NMSC are treated by MMS Howard W. Rodgers, Brea M. Coldiron, Dermatol Surg 2013;39:35-42. Asgari M.M., Olson J.M., Alam M. Dermatol Clin 2012; 30: 167-175.

MOHS surgery (ab)use became a hot issue

Na>onal report - - Mohs surgeons are experiencing a dras>c reduc>on in reimbursement due to a change in Medicare policy. The gap can be 23 percent or more, depending on how many procedures are performed on the same day.

Dermatol Surg 2012;38:1435 1436.

Mohs micrographic surgery is facing scru>ny due to increased u>liza>on. The use of Mohs surgery is increasing more rapidly than is the incidence of skin cancer, and this is an area of concern for payers. The value of Mohs surgery in trea>ng skin cancer, reimbursement for the procedure, and our con>nued ability to perform Mohs surgery are, in a manner of speaking, under the microscope.

SAN FRANCISCO Dermatologists and dermatologic surgeons risk a decreased reimbursement value for Mohs surgery if they don t review the published criteria on its appropriate use, according to Dr. Sumaira Aasi. "The reason is, at the end of the day, we might be killing the goose that laid the golden egg ourselves" if too many Mohs surgeries are done for inappropriate reasons, said Dr. Aasi of Stanford (Calif.) University. There are an estimated 4 million nonmelanoma skin cancers in the United States each year, and the use of Mohs surgery increased by 400% from 1995 to 2009, Dr. Aasi said (Dermatol. Clin. 2012;30:167-75).

Dr. Brea Coldiron removes suspected cancerous skin cells from a pa>ent during Mohs surgery at The Skin Cancer Center in Cincinna>, Ohio. CreditLuke Sharrea for The New York Times

J Am Acad Dermatol 2012;67:531-50 & Dermatol Surg 2012;38:1581

How is it working???

MOHS micrographic surgery Principles developed in the early 1930 s by Dr. Frederic E. Mohs at the Wisconsin University Basic concepts: Ver%cally cut sec%ons of excised cancerous >ssue will never give a complete microscopic marginal control Horizontal complete layers of >ssue from the tumor bed can obtain such a control

MOHS micrographic surgery - advantages l Intra- opera>ve pathological examina>on of the whole tumor bed =>complete microscopic margin control is achieved l Result - > local recurrence rates are significantly lower, especially for certain histological subtypes & loca>ons of high risk van Loo E, Mosterd K, Krekels GAM, et al. Eur J Cancer 2014; 50:3011 3020.

Simple surgical excision disadvantages l Regular pathological secfoning & examinafon is based on sampling representafve cuts

1

2

3

4

5

6

CERTAIN TUMORS ARE ASSOCIATED WITH HIGHER RECURRENCE RATE AND POORER PROGNOSIS PrognosFc factor Tumor size Tumor site DefiniFon of clinical margins Histological subtype Histological features of aggression Failure of previous treatment Immunosuppression Comment Tumor size (diameter greater than 2 cm) correlates with higher risk of recurrence and metastases Lesions on the central face, especially around the eyes, nose, lips and ears are at higher risk of recurrence Poorly defined lesions are at higher risk of recurrence Certain subtypes confer higher risk of recurrence and metastases Perineural and/or perivascular involvement confers higher risk of recurrence PaFents who had BCC have 10 Fmes higher risk of developing subsequent BCC compared to general populafon Recurrent lesions are at a higher risk of further recurrence and metastases Confers increased risk of recurrence and metastases (e.g. recipients of solid- organ transplants) Telfer NR et al. Br J Dermatol 2008;159:35 48. Rubin AI et al. N Engl J Med 2005;353:2262 9.

MOHS micrographic surgery - advantages l Only tumor and the whole tumor is taken out => No need for safety margins l Result - > maximal healthy /ssue sparring can be achieved, especially important for cosme%cally sensi%ve areas, fingers and genitalia Muller FM, Dawe RS, Moseley H, Fleming CJ. Dermatol Surg 2009; 35:1349 54.

Simple surgical excision disadvantages l Ordinary tumor excision requires arbitrary safety margins

Guidelines for the management of BCC Small (<20mm) well defined BCC: 3mm healthy appearing skin margin (HASM) = 85% of lesions are clear 4-5mm HASM = 95% of lesions are clear 5% of tumors extend more then 4-5 mm beyond visual margin 2 1 0.5 N.R. Telfer, G.B. Colver and C.A. Morton Br J Dermatol 2008 159, 35 48.

Guidelines for the management of BCC Primary morpheiform BCC lesions: 3mm HASM = 66% of lesions are clear 5mm HASM = 82% 13-15mm HASM = >95% 1 2 0.5 N.R. Telfer, G.B. Colver and C.A. Morton Br J Dermatol 2008 159, 35

0.3 Dermoscopically diagnosed Primary, superficial appearing, 3mm BCC Guidelines recommended safety margins make a 1.3cm excision

Single stage MOHS => complete clearance, excellent cosme>c result and a 100% clear margin by MOHS technique with only 1mm margin! Dermablade 1 st stage with 1mm margin from dermoscopic lesion edge

IndicaFons - summary NMSC tumors arer (mul>ple) local recurrence Primary NMSC tumors in high risk loca>ons, tumors of certain histologic subtypes with aggressive features, big lesions on esthe>cal/func>onal sensi>ve areas Other tumors - Len>go maligna - Dermatofibrosarcoma protuberans - Merkel cell carcinoma - Microcys>c adnexal carcinoma - Extramammary Paget s disease - Sebaceous carcinoma..

THANK YOU!!! mzamir@hadassah.org.il